Navigation Links
Multiple disease-related research gets green light from the NIH
Date:9/16/2008

Saranac Lake, N.Y. - Stephen Smiley, Ph.D., a member of the scientific faculty at the Trudeau Institute, whose research could lead to new treatments for several common diseases, has been awarded a research grant from the National Institutes of Health (NIH) for nearly $2 million.

Dr. Smiley and members of his laboratory are working to develop treatments for a number of diseases where an abnormal activation of blood coagulation pathways causes damage to the body. The diseases include multiple sclerosis (MS), rheumatoid arthritis, transplant rejection and sepsis, a leading cause of hospital deaths. In particular, Dr. Smiley's laboratory is studying fibrin, a blood-clotting protein that frequently accumulates at high levels in diseased tissues. These high levels of fibrin are thought to clog blood vessels and cause inflammation, thereby starving tissues of oxygen and increasing the severity of disease.

With prior funding from the NIH, Dr. Smiley's laboratory collaborated with Trudeau colleague Larry Johnson to demonstrate that, despite the risks it poses, fibrin also performs critical protective functions during immune responses.

The researchers showed that fibrin deposition is essential for survival during certain infections. Specifically, they found that fibrin staunches bleeding caused by protective immune cells as they rid the body of infected cells. In addition to protecting against this collateral damage caused by the immune system itself, Drs. Smiley and Johnson also discovered that fibrin suppresses the growth of some unhealthy bacteria.

These prior studies led the scientists to hypothesize that the human body needs to maintain a careful balance of proper fibrin levels during immune responses: "Some fibrin deposition is essential for good health, while too much can be dangerous and harmful," explained Dr. Smiley.

"I'm very pleased the NIH is continuing to support Dr. Smiley's research," said David L. Woodland, Ph.D., president and director of the Trudeau Institute. "Cutting-edge research of this caliber has the potential to lead to improved treatments for people afflicted with a number of debilitating diseases, in addition to those who suffer transplant rejections."

Dr. Smiley believes that prior attempts to treat patients suffering from sepsis by removing fibrin failed because those treatments most likely removed both unhealthy and healthy fibrin. With this infusion of research funds, Dr. Smiley's laboratory will now seek to identify what exactly tips the balance between healthy and unhealthy levels of fibrin. They recently discovered that cytokines, soluble signaling molecules within the immune system, play a primary role in regulating this balance. Now they are using a variety of models and methods to delineate precisely how cytokines regulate fibrin levels.

The NIH funds will support Dr. Smiley's research efforts over a four-year period.


'/>"/>

Contact: Brian Turner
brianturner@trudeauinstitute.org
518-891-3080
Trudeau Institute
Source:Eurekalert  

Related biology news :

1. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
2. Nicotinic receptors may be important targets for treatment of multiple addictions
3. Emphasis on conifer forests places multiple species at risk
4. For honey bee queens, multiple mating makes a difference
5. Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone
6. New magnetic separation technique might detect multiple pathogens at once
7. The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source
8. Multiple species of bacteria may cause trachoma: Implications for treatment
9. Multiple resource management is focus of new technical report
10. Potential new target for multiple sclerosis therapy
11. Fast AFM probes measure multiple properties of biomolecules or materials simultaneously
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Multiple disease-related research gets green light from the NIH
(Date:5/6/2017)... May 5, 2017 RAM Group ... a new breakthrough in biometric authentication based on ... mechanical properties to perform biometric authentication. These new sensors ... material created by Ram Group and its partners. This ... transportation, supply chains and security. Ram Group is ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... The award-winning ... to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... is faced with the challenge of how to continue to feed a growing nation. ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... and applications consulting for microscopy and surface analysis, Nanoscience Instruments is now ... Analytical offers a broad range of contract analysis services for advanced applications. ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October 24th, ... INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will ... free and open to the public, but registration is required. , WHAT: ...
Breaking Biology Technology: